Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range ...

Hims & Hers on Monday released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...

Patients report that GLP-1 drugs like Ozempic and Mounjaro reduce “food noise,” the constant mental chatter about eating.

Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...

(Reuters) - Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in ...

Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.

New research reveals men and women process breakfast nutrients differently, reshaping weight loss strategies with a focus on ...

The telehealth company Hims & Hers has made waves for its Super Bowl ad that plugged its lower-priced form of injectable ...

Legislators may launch a study of how weight loss drugs might reduce costs in the Iowa Medicaid program. Jeffrey Boeyink is a ...